253 related articles for article (PubMed ID: 33843701)
1. Impact of maternal medication for opioid use disorder on neurodevelopmental outcomes of infants treated for neonatal opioid withdrawal syndrome.
King RS; Peacock-Chambers E; Wilson D; Shimer J; Foss S; Visintainer P; Singh R
J Neonatal Perinatal Med; 2021; 14(4):463-473. PubMed ID: 33843701
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Impact of Prenatal Medication for Opioid Use Disorder on Discharge Home With Parents Among Infants With Neonatal Opioid Withdrawal Syndrome.
Singleton R; Rutz S; Day G; Hammes M; Wilson AS; Herrick M; Mazut C; Brunner L; Prince J; Desnoyers C; Shaw J; Hirschfeld M; Palis H; Slaunwhite A
J Addict Med; 2022 Nov-Dec 01; 16(6):e366-e373. PubMed ID: 35245916
[TBL] [Abstract][Full Text] [Related]
3. Prenatal Use of Medication for Opioid Use Disorder and Other Prescription Opioids in Cases of Neonatal Opioid Withdrawal Syndrome: North Carolina Medicaid, 2016-2018.
Austin AE; Bona VD; Cox ME; Proescholdbell S; Fliss MD; Naumann RB
Am J Public Health; 2021 Sep; 111(9):1682-1685. PubMed ID: 34383554
[No Abstract] [Full Text] [Related]
4. Outcomes associated with the use of medications for opioid use disorder during pregnancy.
Krans EE; Kim JY; Chen Q; Rothenberger SD; James AE; Kelley D; Jarlenski MP
Addiction; 2021 Dec; 116(12):3504-3514. PubMed ID: 34033170
[TBL] [Abstract][Full Text] [Related]
5. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
6. Severity of neonatal opioid withdrawal syndrome with prenatal exposure to serotonin reuptake inhibitors.
Bakhireva LN; Sparks A; Herman M; Hund L; Ashley M; Salisbury A
Pediatr Res; 2022 Mar; 91(4):867-873. PubMed ID: 34588611
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Subsequent Pregnancies of Individuals With Opioid Use Disorder Treated in Multidisciplinary Clinic in Prior Pregnancy.
Mason I; Mashburn S; Cleary E; Abdelwahab M; Ma'ayeh M; Rood KM
J Addict Med; 2022 Jul-Aug 01; 16(4):420-424. PubMed ID: 35960213
[TBL] [Abstract][Full Text] [Related]
8. Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.
Bakhireva LN; Holbrook BD; Shrestha S; Leyva Y; Ashley M; Cano S; Lowe J; Stephen JM; Leeman L
Early Hum Dev; 2019 Jan; 128():69-76. PubMed ID: 30554024
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome.
Devlin LA; Hu Z; Ounpraseuth S; Simon AE; Annett RD; Das A; Fuller JF; Higgins RD; Merhar SL; Smith PB; Crawford MM; Cottrell LE; Czynski AJ; Newman S; Paul DA; Sánchez PJ; Semmens EO; Smith MC; Whalen BL; Snowden JN; Young LW;
Matern Child Health J; 2023 Jun; 27(6):1030-1042. PubMed ID: 36905529
[TBL] [Abstract][Full Text] [Related]
10. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018.
Mallinson DC; Kuo HD; Kirby RS; Wang Y; Berger LM; Ehrenthal DB
Prev Med; 2024 Apr; 181():107914. PubMed ID: 38408650
[TBL] [Abstract][Full Text] [Related]
11. Delivery timing for the opioid-exposed infant.
Sanusi A; Gray M; Xue Y; Mohr S; Curtis P; Dismukes J; Gentle S; Szychowski JM; Brocato B; Casey B; Harper L; Sinkey R
Am J Obstet Gynecol MFM; 2022 Nov; 4(6):100719. PubMed ID: 35977700
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the Normalization Effects of Medication for Opioid Use Disorder on Functional Connectivity in Neonates with Prenatal Opioid Exposure.
Liu J; Grewen K; Gao W
J Neurosci; 2022 Jun; 42(22):4555-4566. PubMed ID: 35552232
[TBL] [Abstract][Full Text] [Related]
13. Differences in Mortality Among Infants With Neonatal Opioid Withdrawal Syndrome.
Austin AE; Di Bona V; Cox ME; Proescholdbell SK; Naumann RB
Am J Prev Med; 2022 Oct; 63(4):619-623. PubMed ID: 35489960
[TBL] [Abstract][Full Text] [Related]
14. Maternal Opioid Use Disorder and the Risk of Postneonatal Infant Mortality.
Grossarth S; Osmundson SS; Wiese AD; Phillips SE; Pham A; Leech AA; Patrick SW; Spieker AJ; Grijalva CG; Adgent MA
JAMA Pediatr; 2023 Jul; 177(7):675-683. PubMed ID: 37155175
[TBL] [Abstract][Full Text] [Related]
15. Hospital Outcomes of Infants with Neonatal Opioid Withdrawal Syndrome at a Tertiary Care Hospital with High Rates of Concurrent Nonopioid (Polysubstance) Exposure.
Morris E; Bardsley T; Schulte K; Seidel J; Shakib JH; Buchi KF; Fung CM
Am J Perinatol; 2022 Mar; 39(4):387-393. PubMed ID: 32892326
[TBL] [Abstract][Full Text] [Related]
16. Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphine.
O'Connor AB; Kelly BK; O'Brien LM
Drug Alcohol Depend; 2017 Nov; 180():200-203. PubMed ID: 28917206
[TBL] [Abstract][Full Text] [Related]
17. Opioids affect the fetal brain: reframing the detoxification debate.
Caritis SN; Panigrahy A
Am J Obstet Gynecol; 2019 Dec; 221(6):602-608. PubMed ID: 31323217
[TBL] [Abstract][Full Text] [Related]
18. Prenatal Risk Factors and Perinatal and Postnatal Outcomes Associated With Maternal Opioid Exposure in an Urban, Low-Income, Multiethnic US Population.
Azuine RE; Ji Y; Chang HY; Kim Y; Ji H; DiBari J; Hong X; Wang G; Singh GK; Pearson C; Zuckerman B; Surkan PJ; Wang X
JAMA Netw Open; 2019 Jun; 2(6):e196405. PubMed ID: 31251378
[TBL] [Abstract][Full Text] [Related]
19. Predictors of pharmacologic therapy for neonatal opioid withdrawal syndrome: a retrospective analysis of a statewide database.
Singh R; Houghton M; Melvin P; Wachman EM; Diop H; Iverson R; Picarillo A; Rhein L; Gupta M;
J Perinatol; 2021 Jun; 41(6):1381-1388. PubMed ID: 33608626
[TBL] [Abstract][Full Text] [Related]
20. Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021.
Miele K; Kim SY; Jones R; Rembert JH; Wachman EM; Shrestha H; Henninger ML; Kimes TM; Schneider PD; Sivaloganathan V; Sward KA; Deshmukh VG; Sanjuan PM; Maxwell JR; Seligman NS; Caveglia S; Louis JM; Wright T; Bennett CC; Green C; George N; Gosdin L; Tran EL; Meaney-Delman D; Gilboa SM
MMWR Surveill Summ; 2023 May; 72(3):1-14. PubMed ID: 37130060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
